# Oral Semaglutide for Alcohol Use Disorder: What a New Randomized Trial Found > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/oral-semaglutide-alcohol-use-disorder-randomized-trial-results/ > **Published:** 2026-08-14T08:59:22-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T22:00:39-04:00 > **Clinical Summary:** Explore findings from the oral semaglutide alcohol use disorder randomized trial showing mixed results with promising secondary outcomes. --- CED Clinical Relevance #100 Clinical Evidence Update A peer-reviewed phase 2 randomized trial tested oral semaglutide in treatment-seeking adults with moderate to severe alcohol use disorder. The primary laboratory craving endpoint was null, while several secondary alcohol outcomes and an exploratory cannabis-use outcome favored semaglutide. Clinical Insight | CED Clinic Schacht and colleagues tested oral semaglutide against placebo in 50 treatment-seeking adults with moderate to severe alcohol use disorder. The primary laboratory craving endpoint was not significantly different, and drinks per day also did not significantly improve. Several secondary alcohol outcomes favored semaglutide, while fewer cannabis-use days appeared in an exploratory analysis. The clinically responsible reading is mixed and preliminary: this is randomized human evidence that supports larger confirmatory trials, not an established treatment recommendation. GLP-1SemaglutideAlcohol Use DisorderRandomized TrialCannabis Use Audience Adults affected by alcohol use disorder, families, addiction clinicians, primary-care clinicians, and readers following GLP-1 and [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) Primary Topic oral semaglutide for alcohol use disorder Source [Read the full source](https://pubmed.ncbi.nlm.nih.gov/42522065/) A phase 2 randomized trial tested oral semaglutide in 50 treatment-seeking adults with moderate to severe alcohol use disorder. The primary laboratory craving endpoint and drinks-per-day outcome did not significantly improve, while several secondary drinking measures favored semaglutide. Cannabis-use days also declined in an exploratory analysis that requires confirmation. What This Study Teaches Us The trial provides a mixed rather than uniformly positive result. Semaglutide did not significantly improve the primary laboratory cue-induced craving endpoint or drinks per day, but it was associated with fewer heavy-drinking days, fewer drinks per drinking day, lower naturalistic craving, fewer alcohol-related consequences, and fewer cannabis-use days in exploratory analysis. Why This Matters GLP-1 receptor agonists are attracting substantial interest in [addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/), but enthusiasm can easily outrun the evidence. This trial matters because it enrolled treatment-seeking adults, used random assignment and placebo control, and reported both null and favorable outcomes rather than reducing the study to a single positive headline. Study Snapshot Study Type Phase 2 double-blind, randomized, parallel-arm, placebo-controlled trial Population 50 treatment-seeking adults with moderate to severe alcohol use disorder Intervention Oral semaglutide, 3 mg daily for 4 weeks followed by 7 mg daily for 4 weeks Comparator Placebo for 8 weeks Primary Outcome Laboratory cue-elicited alcohol craving at week 6 Primary Result No statistically significant difference from placebo Key Null Secondary Result No statistically significant reduction in drinks per day Favorable Secondary Signals Heavy-drinking days, drinks per drinking day, naturalistic craving, alcohol-related consequences, and WHO risk drinking level Exploratory Cannabis Outcome Cannabis-use days declined relative to placebo; this was exploratory rather than a primary endpoint Journal The American Journal of Psychiatry Published July 29, 2026 PMID / DOI 42522065 / 10.1176/appi.ajp.20260003 Major Limitation Small sample, eight-week duration, multiple secondary outcomes, and exploratory cannabis analysis Clinical Bottom Line Oral semaglutide did not improve the trial’s primary laboratory craving endpoint, but several clinically relevant secondary alcohol outcomes favored treatment. The findings justify larger confirmatory trials, not routine semaglutide prescribing for alcohol use disorder. The Primary Endpoint Was Negative At week 6, oral semaglutide did not significantly reduce laboratory cue-elicited alcohol craving compared with placebo. That null primary result must remain central. Positive secondary outcomes do not retroactively convert the primary endpoint into a success. Several Secondary Outcomes Favored Semaglutide Semaglutide was associated with fewer heavy-drinking days, fewer drinks per drinking day, lower naturalistic alcohol craving, and a faster reduction in alcohol-related consequences. More participants receiving semaglutide reduced their World Health Organization risk drinking level by at least one category. The Cannabis Finding Was Exploratory Cannabis-use days declined relative to placebo, with a reported regression coefficient of -1.434 and a 95% confidence interval from -2.568 to -0.301. Cannabis use was not the primary focus of the trial. The result should be treated as a signal for future study, not evidence that semaglutide treats [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/). Why Treatment-Seeking Participants Matter The trial enrolled adults seeking treatment for moderate to severe alcohol use disorder, a clinically different population from people taking GLP-1 medicines primarily for diabetes or [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/). Even so, 50 participants and eight weeks are not enough to establish long-term effectiveness, safety, relapse prevention, or comparative value against approved alcohol-use-disorder treatments. What the Trial Cannot Establish The abstract does not establish an optimal dose, treatment duration, durability after discontinuation, or which patients are most likely to benefit. It also does not support self-directed use or a general conclusion that GLP-1 receptor agonists reduce every addictive behavior. How Strong Is This Evidence? Random assignment, placebo control, double blinding, treatment-seeking participants, preregistered outcomes, and clinically interpretable drinking measures strengthen the study. Where This Paper Deserves Skepticism The sample included only 50 participants and treatment lasted eight weeks. The primary laboratory craving endpoint and drinks-per-day outcome were null, several favorable results were secondary, and the cannabis finding was exploratory. What This Paper Does Not Show The trial does not prove that semaglutide is an established treatment for alcohol use disorder or [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/). It does not establish long-term benefit, relapse prevention, comparative effectiveness, or a safe self-treatment approach. How This Fits With the Broader Clinical Conversation The emerging GLP-1 addiction literature now includes randomized, observational, and mechanistic work. Each design answers a different question, and small positive trials still require larger replication. For patients, the practical discussion should include established alcohol-use-disorder treatments, metabolic indications, gastrointestinal and other medication risks, concurrent substance use, and the reason semaglutide is being considered. Dr. Caplan’s Take *I would describe this as encouraging but mixed evidence. A negative primary endpoint deserves the same attention as the favorable secondary outcomes.* *The exploratory reduction in cannabis-use days is especially interesting for CED readers, but it is not a treatment claim. It is a reason to design a cannabis-focused trial with a prespecified endpoint and adequate power.* What a Careful Reader Should Take Away A careful reader should see a small randomized trial with a null primary endpoint, several favorable secondary alcohol outcomes, and an exploratory cannabis signal that needs direct replication. Evidence Interpretation Guide Table of Contents - [How to Read a Trial With a Null Primary Endpoint and Positive Secondary Signals](#How_to_Read_a_Trial_With_a_Null_Primary_Endpoint_and_Positive_Secondary_Signals)[Four distinctions that matter](#Four_distinctions_that_matter) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Do Not Self-Prescribe](#Do_Not_Self-Prescribe) - [Keep the Null Primary Endpoint Visible](#Keep_the_Null_Primary_Endpoint_Visible) - [Small Trials Can Produce Unstable Estimates](#Small_Trials_Can_Produce_Unstable_Estimates) - [Secondary Outcomes Need Confirmation](#Secondary_Outcomes_Need_Confirmation) - [A Treatment-Seeking Sample Adds Context](#A_Treatment-Seeking_Sample_Adds_Context) - [AUD Care Already Has Evidence-Based Options](#AUD_Care_Already_Has_Evidence-Based_Options) - [Prespecify Cannabis Outcomes](#Prespecify_Cannabis_Outcomes) - [Avoid Indication Creep](#Avoid_Indication_Creep) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Read a Trial With a Null Primary Endpoint and Positive Secondary Signals The hierarchy of outcomes matters. A mixed result can still be informative when each finding is kept in its proper place. ### Four distinctions that matter **Primary versus secondary**The primary laboratory craving endpoint was null; several secondary drinking outcomes favored semaglutide. **Laboratory versus naturalistic**Cue-induced craving in the laboratory and craving reported in daily life are related but not interchangeable outcomes. **Alcohol versus cannabis**Alcohol use disorder defined the trial, while cannabis-use days were explored as an additional outcome. **Signal versus treatment standard**A small phase 2 trial can justify larger studies without establishing routine clinical use. The Research Question Can oral semaglutide improve craving and drinking outcomes in treatment-seeking adults with alcohol use disorder? The Patient Question Does this trial mean semaglutide is appropriate for my alcohol or cannabis use? The Bottom Line The results are encouraging in several secondary outcomes, but they are not sufficient for a general treatment recommendation. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview Eight perspectives help separate the randomized signal from the unanswered questions about outcome hierarchy, durability, safety, and clinical use. #### Do Not Self-Prescribe This study is not a reason to seek semaglutide outside an appropriate clinical indication and prescribing relationship. The interpretation should remain matched to this eight-week phase 2 trial. Lens takeaway Discuss both alcohol-use treatment and metabolic health with a qualified clinician. #### Keep the Null Primary Endpoint Visible The favorable secondary outcomes are clinically interesting, but interpretation should begin with the nonsignificant primary endpoint. The interpretation should remain matched to this eight-week phase 2 trial. Lens takeaway Mixed trial results call for proportionate counseling. #### Small Trials Can Produce Unstable Estimates With 50 participants and multiple outcomes, effect estimates may change materially in a larger trial. The interpretation should remain matched to this eight-week phase 2 trial. Lens takeaway Replication matters more than enthusiasm. #### Secondary Outcomes Need Confirmation Heavy-drinking days and craving outside the laboratory may matter clinically, but they were not the primary endpoint. The interpretation should remain matched to this eight-week phase 2 trial. Lens takeaway Outcome hierarchy should guide confidence. #### A Treatment-Seeking Sample Adds Context This trial extends earlier work by studying treatment-seeking adults with moderate to severe alcohol use disorder using oral dosing. The interpretation should remain matched to this eight-week phase 2 trial. Lens takeaway Population and formulation differences prevent simple pooling by headline. #### AUD Care Already Has Evidence-Based Options Semaglutide should not displace established behavioral and pharmacologic alcohol-use-disorder care on the basis of this trial. The interpretation should remain matched to this eight-week phase 2 trial. Lens takeaway New evidence belongs inside comprehensive care. #### Prespecify Cannabis Outcomes A future cannabis-focused trial should define use frequency, [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), craving, product exposure, and functional outcomes before enrollment. The interpretation should remain matched to this eight-week phase 2 trial. Lens takeaway Exploratory signals should generate direct tests. #### Avoid Indication Creep Public discussion should distinguish research interest from an established indication and should not imply class-wide addiction efficacy. The interpretation should remain matched to this eight-week phase 2 trial. Lens takeaway Accurate labeling of uncertainty protects patients. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Oral+Semaglutide+for+Alcohol+Use+Disorder%3A+What+a+New+Randomized+Trial+Found&url=https%3A%2F%2Fcedclinic.com%2Foral-semaglutide-alcohol-use-disorder-randomized-trial%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Foral-semaglutide-alcohol-use-disorder-randomized-trial%2F) [BlueSky](https://bsky.app/intent/compose?text=Oral+Semaglutide+for+Alcohol+Use+Disorder%3A+What+a+New+Randomized+Trial+Found%20https%3A%2F%2Fcedclinic.com%2Foral-semaglutide-alcohol-use-disorder-randomized-trial%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/42522065/) Related Reading at CED Clinic Continue exploring the evidence [GLP-1 and Cannabis Use Disorder: The BMJ Study Explained](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) CED context on observational GLP-1 findings related to cannabis use disorder and substance-related outcomes. [Read the cannabis-use-disorder context](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) [GLP-1 Drugs, Semaglutide, and the Future of Alcohol Addiction Treatment](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) A broader review of GLP-1 receptor agonists in alcohol-use-disorder research and the limits of the developing evidence. [Review the broader GLP-1 evidence](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) [Endocannabinoid System and Alcohol Use Disorder](https://cedclinic.com/endocannabinoid-system-alcohol-use-disorder-evidence/) Related context on alcohol use, reward pathways, cannabinoid biology, and the boundary between mechanistic and clinical evidence. [Compare the alcohol-use evidence](https://cedclinic.com/endocannabinoid-system-alcohol-use-disorder-evidence/) Similar Studies on CEDClinic.com Earlier coverage on closely related evidence When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved. Related digest item [Endocannabinoid System & Alcohol Use Disorder: Evidence from Preclinical & Human Studies](https://cedclinic.com/endocannabinoid-system-alcohol-use-disorder-evidence/) The [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) alcohol use disorder evidence highlights its role in regulating reward, stress, and emotional processing. Preclinical studies show cannabinoid receptor modulators reduce alcohol intake. Howeve… Covers a closely related topic; this CED post is older by about 37 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/endocannabinoid-system-alcohol-use-disorder-evidence/) Related digest item [GLP-1 and Cannabis Use Disorder: The BMJ Study Explained](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) A BMJ cohort study of 606,434 veterans found GLP-1 drugs reduced cannabis use disorder risk by 14% and SUD-related deaths by 50%. Full clinical breakdown. Covers a closely related topic; this CED post is older by about 40 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Related digest item [GLP-1 Medications May Quiet the Craving Behind Addiction](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) A landmark BMJ study published June 3, 2026 found that GLP-1 receptor agonists like semaglutide significantly reduced both the development and severity of substance use disorders in over 600,000 U.S. veterans. Cannabis… Covers a closely related topic; this CED post is older by about 54 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Related digest item [GLP-1 Drugs, Semaglutide, and the Future of Alcohol Addiction Treatment](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) GLP-1 receptor agonists for alcohol use disorder are attracting growing scientific interest as potential tools for reducing alcohol consumption and relapse risk. This review examines preclinical evidence, observational… Covers a closely related topic; this CED post is older by about 56 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Related digest item [Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Wegovy and Monjaro](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) GLP-1 receptor agonists offer significant health benefits but raise ethical concerns about long-term safety, access equity, and societal impacts. Covers a closely related topic; this CED post is older by about 56 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Related digest item [GLP-1 agonists in addiction therapy – review](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) GLP-1 receptor agonists show promise in reducing alcohol consumption and cravings, as well as supporting nicotine abstinence. However, more research is needed for stimulant use disorders. Covers a closely related topic; this CED post is older by about 56 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Related digest item [GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) GLP-1RAs show promise in reducing antipsychotic-induced weight gain without worsening psychiatric symptoms, offering a new approach for SPMI patients. Covers a closely related topic; this CED post is older by about 56 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Related digest item [GLP-1 therapies- an emerging approach for alcohol reduction?](https://cedclinic.com/glp-1-therapies-an-emerging-approach-for-alcohol-reduction/) A recent study found that semaglutide significantly reduced heavy drinking days and alcohol craving in adults with alcohol use disorder and obesity, offering a promising new approach. Covers a closely related topic; this CED post is older by about 56 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/glp-1-therapies-an-emerging-approach-for-alcohol-reduction/) Related digest item [GLP‑1 Receptor Agonist Treatment and Health Outcomes in Methadone‑Treated Patien](https://cedclinic.com/glp1-receptor-agonist-treatment-and-health-outcomes-in-methadonetreated-patien/) GLP-1 receptor agonists significantly reduced myocardial infarctions, opioid overdoses, and suicidal ideation in methadone-treated OUD patients with T2D. Covers a closely related topic; this CED post is older by about 56 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/glp1-receptor-agonist-treatment-and-health-outcomes-in-methadonetreated-patien/) ## Frequently Asked Questions What was the main question in this trial? The trial tested whether eight weeks of oral semaglutide reduced cue-induced alcohol craving and drinking outcomes in treatment-seeking adults with moderate to severe alcohol use disorder. Did semaglutide improve the primary outcome? No. Laboratory cue-elicited craving at week 6 was not significantly different from placebo. Which alcohol outcomes favored semaglutide? Heavy-drinking days, drinks per drinking day, naturalistic craving, alcohol-related consequences, and improvement in World Health Organization risk drinking level favored semaglutide. Did drinks per day significantly improve? No. The abstract reports no significant difference in drinks per day compared with placebo. What happened to cannabis use? Cannabis-use days declined relative to placebo in an exploratory analysis. The trial was not designed to establish semaglutide as a cannabis-use-disorder treatment. How many people participated? Fifty treatment-seeking adults with moderate to severe alcohol use disorder were randomized. What dose was tested? Participants assigned to semaglutide received 3 mg orally each day for four weeks, followed by 7 mg daily for four weeks. Is semaglutide now a proven alcohol-use-disorder treatment? No. The mixed findings from this small phase 2 trial require confirmation in larger and longer studies. Can these findings be generalized to every GLP-1 medicine? No. Drugs, formulations, doses, populations, and outcomes differ, so this result should not be generalized across the class. What is the practical takeaway? The study supports continued research while established alcohol-use-disorder care remains the clinical foundation. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).